Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genocea Biosciences (DE:GBI1)
BERLIN:GBI1
Genocea Biosciences (GBI1) Stock Price & Analysis
0 Followers
GBI1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.01 - €0.01
Previous Close€0.01
Volume0.00
Average Volume (3M)N/A
Market Cap
€55.00
Enterprise Value-€11.62M
Total Cash (Recent Filing)$20.10M
Total Debt (Recent Filing)$7.65M
Price to Earnings (P/E)N/A
Beta0.23
Next Earnings
Feb 16, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,783,503
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.19
R-Squared0.08
Alpha-0.00192
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)378.83
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-6.08
Enterprise Value/Gross Profit-7.08
Enterprise Value/Ebitda0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
GBI1 FAQ
What was Genocea Biosciences’s price range in the past 12 months?
Genocea Biosciences lowest stock price was €0.01 and its highest was €0.01 in the past 12 months.
What is Genocea Biosciences’s market cap?
Currently, no data Available
When is Genocea Biosciences’s upcoming earnings report date?
Genocea Biosciences’s upcoming earnings report date is Feb 16, 2023 which is 442 days ago.
How were Genocea Biosciences’s earnings last quarter?
Currently, no data Available
Is Genocea Biosciences overvalued?
According to Wall Street analysts Genocea Biosciences’s price is currently Overvalued.
Does Genocea Biosciences pay dividends?
Genocea Biosciences does not currently pay dividends.
What is Genocea Biosciences’s EPS estimate?
Genocea Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genocea Biosciences have?
Currently, no data Available
What happened to Genocea Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Genocea Biosciences?
Currently, no hedge funds are holding shares in DE:GBI1
---
Company Description
Genocea Biosciences
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
---
Technical Analysis
Genocea Biosciences
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Moderna
―
Vir Biotechnology
―
---